Across TCGA pan-cancer cohorts, E2F4 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated E2F4 data layer compared with 4 for mutation status and 4 for mass-spec protein.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher E2F4 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated E2F4 expression acts as an unfavorable survival marker, although some lineages such as SCLC and UCS show a favorable association.
LIHC, HNSC, and ACC are the cancer types where E2F4 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.